pvct8k52714.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  May 27, 2014


PROVECTUS BIOPHARMACEUTICALS, INC.
 (Exact name of registrant as specified in charter)



Delaware
001-36457
90-0031917
(State or other jurisdiction
(Commission
(IRS Employer
of  incorporation)
File Number)
Identification No.)


7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)

(866) 594-5999
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
      
 
 
 

Item 7.01.
Regulation FD Disclosure.
 
On May 27, 2014, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing that it would hold a conference call on Tuesday, June 3, 2014 to discuss the scientific content of two poster presentations at the American Society of Clinical Oncology (ASCO) annual meeting and the regulatory path for the Company’s oncology drug PV-10. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.                  Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit
Number                      Description

99.1                      Press Release, dated May 27, 2014

 
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  May 27, 2014
 
 
PROVECTUS BIOPHARMACEUTICALS, INC.


 
  By: /s/ Peter R. Culpepper  
  Peter R. Culpepper
  Chief Financial Officer and Chief Operating Officer
 
 
 

 
EXHIBIT INDEX


Exhibit Number
  
Description
     
99.1
  
Press release dated May 27, 2014